compani
posit diabet franchis
market trend support continu strength trulic
recent launch novo nordisk cover eu pharma jain/parri
rybelsu weigh share given share eros concern lilli trulic
consensu forecast seen signific shift recent trulic declin
cumul ozempic/rybelsu increas
period address shift dynam diabet market talk
sever kol evalu emerg market trend use iqvia brandimpact data
understand concern diabet price think compound-annual-growth-rate
class tailwind class-lead persist
rate drive trulic share stabil consensu forecast alreadi assum
deceler trulic go still
see linear demand curv rybelsu like impact trulic
updat lilli forecast trulic diabet franchis maintain
po reiter buy rate stock conjunct market
analysi also built global diabet market analysi outlin current futur
share dynam across basal insulin class
concern initi rybelsu impact larg overblown
see bear thesi neg trulic growth due rybelsu less like given
continu strength trulic market share growth sinc ozemp
launch kol discuss suggest initi uptak primarili new patient
primari care set initi specialist demand mainli driven heavier
discount moreov inject trulic show better real-world lower
cardiovascular benefit due adher issu rybelsu oral
therapi competit price ultim market opportun could
limit rybelsu consensu launch expect look
optimist us project doubl digit growth trulic
lilli could usurp current approv oral inject therapi
due host call today slide et dr mcmahon
adjunct professor discuss evolv state diabet landscap
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani
larg diversifi
biopharmaceut compani develop drug
treatment varieti disord includ
diabet migrain cancer rang
busi develop drug
year time
compani retain focu almost exclus
remain differenti versu peer
revenu non-gaap ep remain
bullish lilli key valu driver trulic
jardianc taltz psoriasi olumi
arthriti emgal migrain verzenio
overal view risk reward profil lilli
compel high qualiti differenti growth
modest expect ad pipelin valu
compani novemb
compani
price object base probability-adjust net present valu npv
analysi franchis vertic includ endocrinolog oncolog
pharmaceut product earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product
risk price object better expect launch compet
product emerg clinic data pipelin asset confirm prior
observ failur effect commerci approv product potenti
drug price system restructur us
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
compani novemb
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani novemb
